Nifty
Sensex
:
:
18210.95
61143.33
-57.45 (-0.31%)
-206.93 (-0.34%)

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 524742 | NSE: CAPLIPOINT

865.70
26-Oct-2021
  • Open
  • High
  • Low
  • Previous Close
  •  855.05
  •  887.05
  •  855.05
  •  850.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  118688
  •  1032.01
  •  1034.80
  •  401.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,540.07
  • 25.29
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,097.56
  • 0.35%
  • 5.60

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.03%
  • 1.99%
  • 20.92%
  • FII
  • DII
  • Others
  • 1.76%
  • 1.14%
  • 5.16%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 21.45
  • 17.83

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 21.37
  • 7.23

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 20.44
  • 11.12

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.54
  • 19.77
  • 17.20

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.01
  • 8.75
  • 4.40

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.27
  • 16.57
  • 11.34

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
300.44
240.08
25.14%
278.71
215.23
29.49%
274.39
228.21
20.24%
268.12
227.20
18.01%
Expenses
207.83
168.48
23.36%
193.02
161.42
19.58%
190.46
160.45
18.70%
180.69
156.09
15.76%
EBITDA
92.61
71.60
29.34%
85.69
53.81
59.25%
83.93
67.76
23.86%
87.43
71.11
22.95%
EBIDTM
30.82%
29.82%
30.75%
25.00%
30.59%
29.69%
32.61%
31.30%
Other Income
9.21
6.49
41.91%
9.46
19.63
-51.81%
5.82
10.34
-43.71%
1.76
6.89
-74.46%
Interest
0.27
0.51
-47.06%
0.32
0.17
88.24%
0.28
0.06
366.67%
0.48
0.08
500.00%
Depreciation
12.03
8.96
34.26%
9.86
8.40
17.38%
9.27
8.42
10.10%
8.88
7.40
20.00%
PBT
89.52
68.62
30.46%
84.97
64.87
30.99%
80.20
69.62
15.20%
79.83
70.52
13.20%
Tax
17.99
14.07
27.86%
17.05
16.01
6.50%
14.06
10.73
31.03%
17.00
13.25
28.30%
PAT
71.53
54.55
31.13%
67.92
48.86
39.01%
66.14
58.89
12.31%
62.83
57.27
9.71%
PATM
23.81%
22.72%
24.37%
22.70%
24.10%
25.81%
23.43%
25.21%
EPS
9.37
7.21
29.96%
8.77
6.46
35.76%
8.52
7.74
10.08%
7.52
7.58
-0.79%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Net Sales
1,121.66
1,061.29
863.20
648.69
539.84
401.65
238.72
251.77
173.09
127.03
107.22
Net Sales Growth
23.16%
22.95%
33.07%
20.16%
34.41%
68.25%
-5.18%
45.46%
36.26%
18.48%
 
Cost Of Goods Sold
498.90
471.74
413.16
288.78
238.18
184.93
121.16
135.62
102.58
84.45
77.36
Gross Profit
622.76
589.55
450.04
359.91
301.66
216.72
117.56
116.15
70.50
42.58
29.85
GP Margin
55.52%
55.55%
52.14%
55.48%
55.88%
53.96%
49.25%
46.13%
40.73%
33.52%
27.84%
Total Expenditure
772.00
732.65
603.13
416.84
344.52
276.84
174.51
192.06
136.90
104.68
96.06
Power & Fuel Cost
-
16.36
14.81
13.76
10.98
9.91
7.56
8.61
3.07
1.12
0.84
% Of Sales
-
1.54%
1.72%
2.12%
2.03%
2.47%
3.17%
3.42%
1.77%
0.88%
0.78%
Employee Cost
-
101.96
67.15
45.58
37.61
29.71
17.92
18.24
12.63
7.69
6.28
% Of Sales
-
9.61%
7.78%
7.03%
6.97%
7.40%
7.51%
7.24%
7.30%
6.05%
5.86%
Manufacturing Exp.
-
69.85
68.23
43.49
37.11
28.56
14.33
16.04
7.42
3.07
1.63
% Of Sales
-
6.58%
7.90%
6.70%
6.87%
7.11%
6.00%
6.37%
4.29%
2.42%
1.52%
General & Admin Exp.
-
38.54
25.50
20.82
12.27
13.78
8.15
7.97
6.54
4.67
3.58
% Of Sales
-
3.63%
2.95%
3.21%
2.27%
3.43%
3.41%
3.17%
3.78%
3.68%
3.34%
Selling & Distn. Exp.
-
18.03
9.95
2.08
5.92
9.41
2.29
2.85
1.46
1.02
0.91
% Of Sales
-
1.70%
1.15%
0.32%
1.10%
2.34%
0.96%
1.13%
0.84%
0.80%
0.85%
Miscellaneous Exp.
-
16.16
4.33
2.33
2.45
0.55
3.10
2.72
3.19
2.66
0.91
% Of Sales
-
1.52%
0.50%
0.36%
0.45%
0.14%
1.30%
1.08%
1.84%
2.09%
5.07%
EBITDA
349.66
328.64
260.07
231.85
195.32
124.81
64.21
59.71
36.19
22.35
11.16
EBITDA Margin
31.17%
30.97%
30.13%
35.74%
36.18%
31.07%
26.90%
23.72%
20.91%
17.59%
10.41%
Other Income
26.25
23.54
41.33
19.03
12.67
9.96
3.66
3.03
3.72
2.10
2.51
Interest
1.35
1.59
0.32
0.58
0.61
0.52
0.34
0.97
0.68
0.77
1.26
Depreciation
40.04
36.97
31.62
23.43
19.00
13.30
7.48
8.38
3.54
1.54
1.24
PBT
334.52
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
22.14
11.17
Tax
66.10
62.19
54.38
50.32
43.74
25.44
14.28
12.26
9.76
8.12
3.14
Tax Rate
19.76%
19.83%
20.18%
22.18%
23.22%
21.03%
23.78%
22.96%
27.35%
36.68%
28.11%
PAT
268.42
242.27
215.00
176.56
144.78
95.61
45.77
41.04
25.85
13.98
8.01
PAT before Minority Interest
258.57
251.43
215.08
176.56
144.63
95.50
45.77
41.13
25.93
14.02
8.03
Minority Interest
-9.85
-9.16
-0.08
0.00
0.15
0.11
0.00
-0.09
-0.08
-0.04
-0.02
PAT Margin
23.93%
22.83%
24.91%
27.22%
26.82%
23.80%
19.17%
16.30%
14.93%
11.01%
7.47%
PAT Growth
22.25%
12.68%
21.77%
21.95%
51.43%
108.89%
11.53%
58.76%
84.91%
74.53%
 
EPS
35.51
32.05
28.44
23.35
19.15
12.65
6.05
5.43
3.42
1.85
1.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Shareholder's Funds
1,185.82
947.91
632.91
363.83
224.76
128.14
93.19
61.74
43.14
33.58
Share Capital
89.71
89.71
51.05
15.12
15.12
15.11
15.11
15.11
15.11
15.11
Total Reserves
1,081.31
848.76
575.01
345.42
209.56
111.40
78.08
46.63
28.03
18.47
Non-Current Liabilities
17.39
24.86
23.42
27.86
19.90
13.69
10.39
10.42
8.66
4.29
Secured Loans
0.00
0.02
0.29
0.32
0.48
0.73
0.88
2.07
3.48
1.55
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
5.70
5.23
0.13
0.00
0.40
1.63
0.82
0.81
0.38
0.27
Current Liabilities
142.85
144.32
86.11
108.67
113.36
125.04
124.97
107.58
83.01
69.20
Trade Payables
88.50
64.14
60.47
94.23
78.60
55.71
41.56
31.50
25.64
21.26
Other Current Liabilities
54.27
79.28
24.20
13.86
33.09
60.39
72.11
66.42
50.85
38.33
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.00
0.05
0.05
0.05
5.20
Short Term Provisions
0.09
0.91
1.44
0.58
1.67
8.94
11.25
9.60
6.47
4.41
Total Liabilities
1,363.60
1,125.75
742.52
500.45
358.38
267.14
228.82
179.92
134.90
107.12
Net Block
305.40
272.50
226.84
169.48
151.83
144.23
113.13
102.24
32.71
27.54
Gross Block
422.57
354.79
271.51
231.79
195.15
180.76
142.71
123.06
50.06
43.36
Accumulated Depreciation
117.17
82.29
44.67
62.31
43.31
36.53
29.58
20.82
17.36
15.82
Non Current Assets
327.80
303.23
248.83
196.34
179.16
148.61
146.95
131.30
96.21
53.41
Capital Work in Progress
13.82
20.12
9.70
15.29
3.42
0.23
30.63
24.54
48.98
12.79
Non Current Investment
0.66
0.56
0.33
0.33
13.24
0.44
0.45
0.44
1.19
1.14
Long Term Loans & Adv.
7.92
10.05
11.95
11.23
10.67
3.71
2.75
3.67
10.83
11.94
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,035.81
822.53
493.69
304.11
179.22
118.53
81.87
48.61
38.70
53.71
Current Investments
10.54
60.23
69.62
46.34
4.20
0.00
0.00
0.00
0.00
0.00
Inventories
179.00
238.23
37.45
28.46
22.29
18.81
13.66
9.79
10.42
6.38
Sundry Debtors
279.36
228.96
159.81
125.88
33.02
7.95
5.66
0.09
0.86
7.28
Cash & Bank
459.58
223.43
152.99
79.28
93.07
68.10
45.37
26.82
16.84
31.80
Other Current Assets
107.33
14.87
9.22
6.88
26.63
23.67
17.18
11.90
10.57
8.25
Short Term Loans & Adv.
87.08
56.81
64.61
17.28
19.31
12.58
11.08
8.16
5.61
4.50
Net Current Assets
892.95
678.21
407.58
195.44
65.86
-6.51
-43.10
-58.97
-44.31
-15.49
Total Assets
1,363.61
1,125.76
742.52
500.45
358.38
267.14
228.82
179.91
134.91
107.12

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Cash From Operating Activity
265.77
44.68
83.42
66.49
67.61
42.40
49.88
59.83
31.95
27.92
PBT
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
22.14
11.17
Adjustment
23.09
7.09
19.12
14.84
8.61
3.87
6.21
2.14
-0.21
-0.25
Changes in Working Capital
-4.80
-177.11
-120.06
-100.38
-38.39
-5.13
1.96
29.32
15.81
18.89
Cash after chg. in Working capital
331.91
99.44
125.94
102.84
91.16
58.78
61.56
67.15
37.75
29.81
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-66.14
-54.76
-42.51
-36.35
-23.55
-16.38
-11.67
-7.32
-5.80
-1.89
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5.36
-54.50
-100.46
-69.02
-36.11
-5.72
-22.66
-43.89
-45.44
-16.44
Net Fixed Assets
-35.46
-43.65
58.45
-48.43
-19.56
-7.66
-25.72
-48.50
-43.00
-16.08
Net Investments
46.59
-27.53
-120.03
-29.43
-17.35
0.01
-0.90
0.75
-0.05
-0.04
Others
-16.49
16.68
-38.88
8.84
0.80
1.93
3.96
3.86
-2.39
-0.32
Cash from Financing Activity
-23.98
79.77
89.79
-11.60
-6.74
-13.95
-8.67
-5.96
-1.48
-1.30
Net Cash Inflow / Outflow
236.44
69.94
72.76
-14.13
24.76
22.73
18.55
9.99
-14.97
10.18
Opening Cash & Equivalents
220.77
150.65
77.17
91.31
66.55
45.37
26.82
16.84
31.80
21.62
Closing Cash & Equivalent
456.96
220.77
150.65
77.17
91.31
68.10
45.37
26.82
16.84
31.80

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Jun 12
Book Value (Rs.)
144.95
114.21
78.03
47.69
29.73
16.25
11.84
7.68
5.22
3.95
ROA
20.20%
23.02%
28.41%
33.68%
30.54%
18.46%
20.12%
16.48%
11.59%
9.00%
ROE
25.65%
29.58%
37.14%
49.43%
54.97%
43.13%
55.78%
53.24%
40.49%
29.10%
ROCE
28.82%
33.35%
45.59%
64.08%
69.03%
55.41%
71.11%
68.99%
56.69%
34.62%
Fixed Asset Turnover
2.73
2.76
2.58
2.53
2.14
1.48
1.89
2.00
2.73
2.61
Receivable days
87.41
82.19
80.37
53.72
18.62
10.40
4.17
1.00
11.66
26.30
Inventory Days
71.75
58.28
18.54
17.16
18.68
24.83
17.00
21.31
24.06
20.01
Payable days
43.93
28.33
65.76
89.68
88.17
103.48
69.75
79.69
85.60
79.07
Cash Conversion Cycle
115.23
112.15
33.15
-18.80
-50.88
-68.24
-48.58
-57.39
-49.89
-32.75
Total Debt/Equity
0.01
0.04
0.00
0.00
0.00
0.02
0.02
0.06
0.12
0.23
Interest Cover
198.29
843.86
391.22
309.72
235.08
179.35
56.11
53.29
29.73
9.88

News Update:


  • Caplin Point’s CRO division completes USFDA audit with nil observations
    24th Sep 2021, 14:04 PM

    The company targets approvals on mutual recognition basis from other regulatory bodies

    Read More
  • Caplin Point Laboratories’ arm gets USFDA’s approval for Labetalol Hydrochloride Injection
    8th Sep 2021, 12:18 PM

    Labetalol hydrochloride Injection had US sales data of approximately $6 million for the 12-month period ending June 2021

    Read More
  • Caplin Point Laboratories’ arm gets approval from Brazil’s ANVISA for sterile injectable manufacturing site near Chennai
    17th Aug 2021, 15:16 PM

    The approval grants access to the company to register and market its products in Brazil

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.